WRBY

Warby Parker Inc. (WRBY) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Warby Parker Inc. is a mission-driven lifestyle brand operating at the intersection of technology, design, healthcare, and social enterprise. The company sells eyewear products and provides optical services through an omnichannel model comprising 287 retail stores (as of March 31, 2025) and an e-commerce platform. The company operates as a single reportable segment: holistic vision care.

Key Financial Metrics

Debt and Liquidity: The company maintains a $120.0 million revolving credit facility with no outstanding borrowings as of March 31, 2025, other than $4.3 million in letters of credit. Total liabilities were $328.7 million, primarily consisting of lease liabilities ($223.7 million).

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 11.9% year-over-year, driven by an 8.7% increase in Active Customers and a rise in Average Revenue per Customer (ARPC) from $296 to $310.
• Profitability: The company achieved GAAP net income of $3.5 million, a turnaround from a net loss of $2.7 million in Q1 2024. Operating income improved from a $5.1 million loss to a $2.5 million profit.
• Margin Compression: Gross margin decreased 40 basis points to 56.3%, attributed to the lower-margin growth of contact lens sales and increased store occupancy costs from new retail openings.
• Expense Management: Selling, General, and Administrative (SG&A) expenses increased 4.2% in absolute dollars but decreased as a percentage of revenue (55.2% vs. 59.3%) due to reduced stock-based compensation and slower corporate expense growth.
• Store Expansion: Retail store count grew from 245 to 287, with 247 stores offering in-person eye exams.

Outlook, Risks, and Management Commentary

• Guidance: The filing does not provide specific numerical guidance for future periods. Management expects operating losses to potentially continue as they invest in business expansion, though they believe current cash and credit facilities are sufficient for the next 12 months.
• Tariff and Supply Chain Risks: Management highlighted significant uncertainty regarding U.S. trade policies and tariffs on imports from China, Italy, Vietnam, and Japan. While mitigation strategies (diversifying suppliers, price adjustments) are in place, further tariff escalation could reduce margins or force price increases.
• Macroeconomic Factors: Elevated inflation and interest rates may impact consumer sentiment and spending, though the company views its products as a medical necessity providing some insulation.
• Legal Contingencies: A class action lawsuit regarding California wage and hour laws has reached a settlement agreement in principle for $1.95 million, subject to court approval. The full amount has been accrued.
• Executive Compensation: In March 2025, the Co-CEOs received a new grant of Performance Stock Units (PSUs) and Restricted Stock Units (RSUs) tied to Total Shareholder Return (TSR) relative to the Russell 2000 Growth Index.

Key Investor Verification Points

• Tariff Impact: Verify the extent of cost increases from new tariffs on eyewear components and the effectiveness of supply chain diversification outside of China.
• Store Economics: Assess the profitability timeline for the 42 new stores opened since Q1 2024 and their impact on occupancy costs and gross margin.
• Contact Lens Margin: Monitor the margin trajectory of the contact lens business, which is currently diluting overall gross margins despite driving volume growth.
• Stock-Based Compensation: Track the volatility in stock-based compensation expenses, particularly related to the vesting of the 2021 and 2025 Founders Grants, which can significantly impact GAAP net income.
• Legal Settlement: Confirm the final court approval status of the $1.95 million wage and hour settlement.